These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12882841)

  • 1. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients.
    Alvarsson M; Sundkvist G; Lager I; Henricsson M; Berntorp K; Fernqvist-Forbes E; Steen L; Westermark G; Westermark P; Orn T; Grill V
    Diabetes Care; 2003 Aug; 26(8):2231-7. PubMed ID: 12882841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up.
    Alvarsson M; Sundkvist G; Lager I; Berntorp K; Fernqvist-Forbes E; Steen L; Orn T; Holberg MA; Kirksaether N; Grill V
    Diabetes Obes Metab; 2008 May; 10(5):421-9. PubMed ID: 17394534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study.
    Alvarsson M; Berntorp K; Fernqvist-Forbes E; Lager I; Steen L; Orn T; Grill V
    Rev Diabet Stud; 2010; 7(3):225-32. PubMed ID: 21409314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
    Hanefeld M; Pfützner A; Forst T; Lübben G
    Curr Med Res Opin; 2006 Jun; 22(6):1211-5. PubMed ID: 16846554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M; Swatko A; Hilberg C; Shestakova M
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment.
    Kärvestedt L; Andersson G; Efendic S; Grill V
    J Intern Med; 2002 Apr; 251(4):307-16. PubMed ID: 11952881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
    Clauson P; Karlander S; Steen L; Efendic S
    Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
    Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
    Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
    Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes.
    Go EH; Kyriakidou-Himonas M; Berelowitz M
    Diabetes Metab Res Rev; 2004; 20(3):225-31. PubMed ID: 15133754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different insulin regimens in elderly patients with NIDDM.
    Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
    Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
    Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.